In fact, infusion of recombinant ANXA1 decreases myocardial infarct size [120] and the treatment with Ac2-26 reduces both infarct size, myeloperoxidase (MPO) and IL-1β levels [121]. Here, ANXA1 is linked to myocardial infarction.